Liminal BioSciences Reports Second Quarter Financial Results 2023

Provided R&D update on GPCR-targeted pipeline, including nomination of lead candidate for OXER1 antagonist programClosed June 30, 2023 with over CAD 19 million cash on hand, expecting to provide...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Canadian ,Bruce Pritchard ,Securities Exchange ,Nasdaq ,Liminal Biosciences Inc ,Exchange Commission ,Arrangement Agreement ,Structured Alpha ,Chief Executive Officer ,Clinical Trial Application ,Investigational New Drug ,Liminal Biosciences ,Canada Business Corporations ,Quarter Ended June ,Securities Act ,Securities Exchange Act ,Liminal Bioscience ,Nasdaq Listing Rule ,Nasdaq Capital Market ,Canadian Securities Administrators ,Annual Report ,Markets ,